A venture investment opportunity in a company that is already a European leader. Impress is the largest and most scalable digital orthodontics platform in Europe, operating in 9 countries and combining AI technologies with a network of light-format clinics. The company demonstrates rapid growth and stable profitability across its key markets.
Regional focus of the project: Impress operates in 9 EU countries and the United Kingdom.
Problem: Key challenges of the orthodontics and aligner market
-
long waiting lists, high prices, and unequal access to treatment;
-
fragmented processes (diagnostics, treatment planning, production — all done in different places);
-
poor quality and risks of DIY-aligners (mail-order kits without medical supervision);
-
many manual processes and inefficient marketing;
-
slow treatment and frequent clinic visits.
Solution and Product Overview
Impress is building a fully integrated platform that includes:
-
diagnostics;
-
AI-driven treatment planning;
-
remote monitoring;
-
payments and administration — in a single stack.
This allows the company to:
-
accelerate treatment by approximately 4 months;
-
reduce the number of clinic visits by ~80%;
-
improve quality and predictability of outcomes;
-
lower costs and increase accessibility.
The company offers:
-
a scalable clinic model (flagship + partner locations);
-
standardized processes and proprietary software;
-
a high level of clinical supervision and safety;
-
recurring revenue through digital services;
-
fast and accurate AI-driven treatment processes.
Market Overview
-
European orthodontics market: $1.5B+, growing rapidly;
-
Aligners continue to replace traditional braces;
-
Regulatory trends strongly support doctor-supervised treatment over DIY methods;
-
Significant market fragmentation enables a leading player to rapidly increase market share.
Tangible and Intangible Assets
1. Tangible assets:
-
a network of 200+ clinics, including 50+ flagship locations;
-
diagnostic and treatment infrastructure;
-
more than 1,000 employees and contractors.
2. Intangible assets:
-
proprietary AI tools (SmileHub, TxPlanner);
-
a standardized operational model;
-
250,000+ treated patients (a large data set);
-
high NPS of 82 and 10% of sales generated through referrals;
-
a strong brand and high market trust.
Current Development Stage and Achievements
-
2025: the first year of positive EBITDA at the group level;
-
key markets (Spain, Italy) already profitable;
-
200+ clinics in 9 countries;
-
250,000+ patients;
-
“Flagship + partners” model has proven scalability;
-
strong referral funnel effect (10% of sales).
Team and Personnel
-
Volodymyr Lupenko (CEO) – product and operations expert, co-founder.
-
Diliara Lupenko (COO) – operational leader, co-founder.
-
Dr. Khaled Kassem – Chief Orthodontist with 20+ years of practice.
Key Current and Target Metrics
Current indicators (2025):
-
Revenue: €150M (run-rate)
-
200+ clinics in 9 countries
-
250,000+ patients
-
Positive group EBITDA; 25–35% EBITDA in key markets
Target indicators (by 2027):
-
2027E Revenue: €279M run-rate
-
Strengthening market share across key European markets
-
Further improvement in margins
-
Preparation for a potential IPO in 2027 with a projected valuation of €2–2.5B
Investment Proposal
A venture-type investment offering returns exclusively through the company’s capital appreciation and later sale of the ICLUB stake, with no dividend payments.
-
Minimum ticket: €10,000; venture model (returns through valuation growth).
-
Timeline: deadline — 15.12.2025
Exit opportunities: management sees a potential IPO in 2027 with a valuation of €2–2.5B.
Additional project information is available after registration in the app via the link or QR code.
Join the private Telegram chat to learn about other relevant investment opportunities: https://t.me/+qNeq1Ir3irZhMTBi
